Clinical Trial

Got Doxy- 'Flipping the Script' on STI PEP

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study is being done to test the effects of doxycycline on inflammation and the bacteria in the body in people with HIV and in people on HIV pre-exposure prophylaxis. This drug is approved by the Food and Drug Administration (FDA) for the treatment of bacterial infections. The study team will investigate whether the drug has additional effects on inflammation or on the bacteria that live in the body.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-10-03; most recent amendment 2026-04-26.
Status change: Not Yet Recruiting → Recruiting 2025-12-09
Trial Details
NCT Number NCT07215325
Lead Sponsor Emory University
Collaborators: National Institute of Allergy and Infectious Diseases (NIAID)
Conditions Sexually Transmitted Infections (STI)
Enrollment 200 participants
Start Date 2025-10-13
Primary Completion 2029-04-13 (estimated)
Study Completion 2029-04-13 (estimated)
Updated on ClinicalTrials.gov 2026-04-30